Smart Contract Audit for Pharma Consent

We map your smart contract logic against HIPAA, GDPR, and 21 CFR Part 11 requirements to identify compliance gaps in data handling, patient consent revocation, and audit trails.

Our threat models focus on pharma-specific risks: consent forgery, unauthorized data access patterns, and manipulation of trial participation records or dosage logs.

Senior auditors conduct line-by-line reviews of consent state machines, role-based access controls (RBAC), and data encryption/decryption flows for critical logic flaws.

We run proprietary and industry-standard tools (Slither, MythX) against your codebase to detect common vulnerabilities (reentrancy, overflows) and gas inefficiencies.

For ultra-critical consent logic, we offer formal verification to mathematically prove the correctness of state transitions and access control invariants.

We provide actionable remediation guidance, verify fixes, and issue a final audit certificate and public attestation to build trust with patients and regulators.

Proactive identification and remediation of critical vulnerabilities like reentrancy, access control flaws, and logic errors before deployment, preventing potential multi-million dollar exploits and data breaches.

Deliver a certified audit report and comprehensive technical documentation that streamlines review by Institutional Review Boards, reducing approval cycles by providing clear evidence of participant data security.

Publicly verifiable audit findings and immutable consent records on-chain increase transparency, building participant confidence and improving recruitment rates for decentralized clinical trials (DCTs).

Mitigate financial and reputational risk by ensuring consent revocation, data access rights, and trial halting mechanisms function as intended, protecting against contractual breaches and litigation.